Inhibition of AXL Signaling in Anti-Metastatic Therapy
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsAmato J. Giaccia, Erinn Bruno Rankin, Jennifer R. Cochran, Douglas Jones, Mihalis Kariolis, Katherine Fuh, Yu Miao
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.
Claims16
A soluble AXL variant polypeptide, wherein said polypeptide lacks the AXL transmembrane domain and comprises at least one amino acid modification relative to the wild-type AXL sequence, and wherein said change increases the affinity of the AXL polypeptide binding to GAS6.
2-3. (canceled)
6-16. (canceled)
20-21. (canceled)
22-33. (canceled)
36-37. (canceled)
A method of determining the ability of a tumor to undergo invasion or metastasis in a subject, said method comprising:
- detecting the level of AXL activity in a biological sample from a subject with a tumor;
- and
- comparing the level of the AXL activity in the biological sample to predetermined level,
- wherein an increase over the predetermined level is indicative of a predisposition of the tumor to invasion or metastasize.
39-42. (canceled)
Dependencies are inferred from the claim text.